TY - JOUR
T1 - Small molecule inhibitors in acute myeloid leukemia
T2 - From the bench to the clinic
AU - Al-Hussaini, Muneera
AU - Dipersio, John F.
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health/ National Cancer Institute (grants NIH/NCI P01 CA101937 [JF DiPersio] and NIH/NCI R01 CA152329 [JF DiPersio]).
PY - 2014/8
Y1 - 2014/8
N2 - Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that has been successful for the treatment of multiple tumors (e.g., gastrointestinal stromal tumors, chronic myelogenous leukemia). Hence, there has been great interest in generating selective small molecule inhibitors targeting critical pathways of proliferation and survival in acute myeloid leukemia. This review highlights a selective group of intriguing therapeutic agents and their presumed targets in both preclinical models and in early human clinical trials.
AB - Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that has been successful for the treatment of multiple tumors (e.g., gastrointestinal stromal tumors, chronic myelogenous leukemia). Hence, there has been great interest in generating selective small molecule inhibitors targeting critical pathways of proliferation and survival in acute myeloid leukemia. This review highlights a selective group of intriguing therapeutic agents and their presumed targets in both preclinical models and in early human clinical trials.
KW - acute myeloid leukemia
KW - small molecule inhibitor
KW - therapeutic agent
UR - http://www.scopus.com/inward/record.url?scp=84904304099&partnerID=8YFLogxK
U2 - 10.1586/17474086.2014.932687
DO - 10.1586/17474086.2014.932687
M3 - Review article
C2 - 25025370
AN - SCOPUS:84904304099
SN - 1747-4086
VL - 7
SP - 439
EP - 464
JO - Expert Review of Hematology
JF - Expert Review of Hematology
IS - 4
ER -